Compare Funko Inc (FNKO) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs IDEXX Laboratories, Inc. — how do they compare? Funko Inc trades at $6.44 (market cap $363.97M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 111.1× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FNKO | IDXX | |
|---|---|---|
Market Cap | $363.97M | $40.43B |
Volume | 1,422,651 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $766.68 |
52-Week Low | $2.81 | $504.70 |
Typical Hold Time | 33 Days | 46 Days |
Enterprise Value | $584.62M | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.44, up 2.06% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised EBITDA guidance, though profitability remains challenged with negative net margins. Analyst sentiment is mixed with a 'Hold' consensus and $7.58 price target, representing 17.7% upside potential from current levels.
Investment outlook balances operational improvements against persistent profitability challenges. The stock offers potential upside from continued execution of the 'Make Culture POP!' strategy and margin expansion, but faces risks from consumer discretionary spending volatility and competitive pressures in the collectibles market.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
